Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML. | King Fahad Medical City | Ongoing | Vidaza | 2 | Version 1.1 | KFMC |
| Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations | PSCDR | Completed | rAAV2 | 1 | rAAV2-VMD2-hMERTK | KFSH & RC-R |
| Perioperative Ischemic Evaluation-3 Tril (POISE-3) | KAIMRC | Ongoing | tranexamic acid | 3 | CT18/008/J | King Abdulaziz Medical City NG (Riyadh) |
| Perioperative Ischemic Evaluation-3 Tril (POISE-3) | KAIMRC | Ongoing | tranexamic acid | 3 | CT18/008/J | King Abdulaziz Medical City NG (Riyadh) |
| "Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation " | Novartis | Ongoing | deferasirox | 2 | CICL670FIC05 | KAUH-J |
| OPEN LABEL, RANDOMIZED, SINGLE SITE CLINICAL TRIAL TO COMPARE THE SAFETY & EFFICACY OF HERBAL MELANIN EXTRACTED FROM NIGELLA SATIVA SEEDS VS STANDARD OF CARE TREATMENT IN TREATING GASTRITIS PATIENTS | KAIMRC | Rejected | Melanole NIGELLA SATIVA | 2 | RC15/152/R | NGHA-R |
| Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) | AstraZeneca | Completed | Osimertinib (AZD9291) | 3 | D5160C00022 | KFSH |
| Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. | Onxeo | Completed | Doxorubicin | 3 | BA2011/03/04 | KAUH-J |
| Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy | Roche | Completed | Tocilzumab | 3b | MA21573 | KFSH & RC-J |
| Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant | ICR Group - International Cancer Research group | Ongoing | palbociclib fulvestrant | 3 | ICRG 1201 | KKUH |